Recruiting
Phase 3

Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

Sponsor:

Alexion Pharmaceuticals, Inc.

Code:

NCT06183931

Conditions

Transthyretin Amyloid Cardiomyopathy

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

ALXN2220

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information